B 316
Alternative Names: B-316Latest Information Update: 09 Jun 2021
At a glance
- Originator FutureGen Biopharmaceutical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Acute myeloid leukaemia
Most Recent Events
- 28 May 2021 Early research in Acute myeloid leukaemia in USA (Parenteral) (FutureGen Pharmaceutical pipeline, May 2021)